Clinical trial · no report yet · Phase 3
POLEM
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
- NCT03827044 ↗
- Terminated
- Royal Marsden NHS Foundation Trust
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- POLEM:Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Exonuclease Domain Mutant Colon Cancer: A Phase 3 Randomised Study
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- POLE Exonuclease Mutant Colon Cancer; Microsatellite Instability; Stage III Colon Cancer
- Interventions
- Avelumab
- Arms
- Avelumab · Experimental
- No intervention · No intervention
- Enrollment
- 30
- Primary outcomes
- Primary End point: Disease Free survival
- Sponsor
- Royal Marsden NHS Foundation Trust with University of Surrey, University of Oxford, Merck KGaA, Darmstadt, Germany
- Start
- Aug 31, 2018
- Primary completion
- Jan 5, 2021
- Results posted
- No
- Registry record
- NCT03827044 · updated Oct 7, 2022
Publications
linked from the registry- Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F, Smith G, Begum R, Crux R, Gillbanks A, Wordsworth S, Chau I, Starling N, Cunningham D, Dhillon T. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open. 2020 Feb;5(1):e000638. doi: 10.1136/esmoopen-2019-000638. PubMed 32079623